CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Reports

We found 7294 result(s)

Rituximab for Rheumatoid Arthritis

Last Updated: September 28, 2006
Result type: Reports

Rituximab (RTX), a monoclonal antibody, selectively targets CD20+ B-cells that are implicated in the pathogenesis of rheumatoid arthritis (RA). The use of RTX with methotrexate (MTX) results in statistically significant clinical improvements among RA patients who have an inadequate response to standard therapies, when compared to the use...

  • Project Number: E0001-000

Open Magnetic Resonance Imaging (MRI) Scanners

Last Updated: November 3, 2006
Result type: Reports

In most MRI scanners, the patient examination table fits inside a long cylindrical tube. Large  patients cannot be accommodated, and some persons experience claustrophobic reactions. Open MRI systems, in which the patient is placed between two plates, overcome these disadvantages. Open MRI scanners are widely used in health care. High-fi...

  • Project Number: E0011-000

Extracorporeal shock wave treatment for chronic plantar fasciitis (heel pain)

Last Updated: January 30, 2007
Result type: Reports

Electrohydraulic, electromagnetic, or piezoelectric devices are used to translate energy into acoustic waves during extracorporeal shock wave treatment (ESWT) for chronic plantar fasciitis (or heel pain). These waves may help to accelerate the healing process via an unknown mechanism. ESWT, which is performed as an outpatient procedure, is in...

  • Project Number: E0009-000

Yttrium-90 Microspheres (TheraSphere® and SIR-Spheres®) for the Treatment of Unresectable Hepatocellular Carcinoma

Last Updated: September 7, 2007
Result type: Reports

Microspheres containing radioactive yttrium-90 (90Y) are infused into the hepatic artery. These deliver high doses of ionizing radiation to inoperable hepatocellular carcinoma, the most common type of primary liver cancer. Limited evidence from several case series indicates that palliative therapy with 90Y microspheres m...

  • Project Number: E0038-000

Grazax ®: An Oral Vaccine for the Treatment of Grass Pollen Allergy (Hay Fever)

Last Updated: November 20, 2007
Result type: Reports

Grazax® is a self-administered, once-daily, tablet-based vaccine that offers an alternative to allergy shots for adults with grass pollen allergy (hay fever). Evidence from three randomized controlled trials indicates modest improvements in hay fever symptoms, with reduced use of medication to control symptoms (rescue medication use) in adult...

  • Project Number: E0033-000

Milnacipran for Fibromyalgia

Last Updated: February 12, 2008
Result type: Reports

Milnacipran is an antidepressant that is under investigation for the treatment of fibromyalgia (a chronic pain disorder). Preliminary evidence suggests that milnacipran may benefit some patients with fibromyalgia, but adverse effects may limit its use. Complete results of phase 3 trials have not yet been published. Further studies are needed ...

  • Project Number: E0057-000

Odanacatib for Postmenopausal Osteoporosis

Last Updated: May 14, 2012
Result type: Reports

Odanacatib belongs to a new class of osteoporosis drugs designed to block cathepsin K, a lysosomal protease that plays a role in the function of osteoclasts. By inhibiting cathepsin K, odanacatib reduces bone resorption by osteoclasts. Odanacatib is not currently licensed for sale in Canada or the United States. Current evidence on the safety...

  • Project Number: EH0004-000

Catheter-Based Renal Denervation for Treatment-Resistant Hypertension

Last Updated: March 27, 2013
Result type: Reports

Renal denervation is a minimally invasive treatment that uses low-level radio frequency energy to disrupt the renal sympathetic nerves in order to reduce blood pressure. The Symplicity Renal Denervation System (Medtronic Inc.) is the first licensed renal denervation device in Canada for treatment-resistant hypertension. Clinical data to suppo...

  • Project Number: EH0006-000

Laquinimod for Relapsing-Remitting Multiple Sclerosis

Last Updated: March 31, 2014
Result type: Reports

Laquinimod is a once daily, synthetic, oral immunomodulator currently under development for the treatment of relapsing-remitting multiple sclerosis (RRMS). Evidence of laquinimod’s efficacy in decreasing the rate of relapse in RRMS is inconsistent. Initial phase II and III placebo-controlled trials favoured laquinimod, but in a later phase II...

  • Project Number: EH0010-000

Remote Ischemic Conditioning for the Reduction of Ischemia-Reperfusion Injury in Acute Myocardial Infarction

Last Updated: February 5, 2015
Result type: Reports

The autoRIC Device is a non-invasive device that provides automated delivery of remote ischemic conditioning (RIC), a temporary stop and restart of blood flow through a series of inflations and deflations of a blood pressure arm cuff. RIC is a novel adjunctive therapy for protection against ischemia-reperfusion injury in patients presenting w...

  • Project Number: EH0020-000